Ramucirumab strongly binds to the human VEGFR-2 and blocks the ability of VEGFR-2 to bind to its ligands VEGF-A/C/D, which leads to the inhibition of cellular proliferation, migration, and permeability in HCC [72]. Here, KDR is linked to hepatocellular carcinoma.